Podcasts about national ovarian cancer coalition

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

In this insightful episode of "Shark Theory," host Baylor Barbee reflects on a recent event organized by his friend Sarah, who works with the National Ovarian Cancer Coalition. The "Together in Teal" walk aimed to support the fight against ovarian cancer. Baylor shares personal anecdotes about his connection to the cause and celebrates the incredible dedication of the event organizers and volunteers. Throughout the episode, Baylor underscores the importance of teamwork, preparation, and commitment to a common goal. He emphasizes that successful events and initiatives require not only the right people but also thorough preparation to prevent chaos. Baylor also discusses the value of creating a cohesive environment where everyone understands the mission and feels like a part of the cause, highlighting Sarah's meticulous planning and the seamless execution of the event. The episode provides listeners with actionable insights on leadership, event planning, and the power of dedication to a meaningful cause. Key Takeaways: Teamwork and Right People: Successful outcomes start with surrounding yourself with the right people who complement each other's skills. Importance of Preparation: Thorough preparation is crucial to prevent chaos and ensure smooth execution of plans. Cohesiveness in Mission: Creating a unified and cohesive environment helps everyone feel part of the cause and work toward common goals. Consistency in Leadership: Consistent energy and actions foster a reliable and trustworthy environment. Commitment to a Cause: Being dedicated to a cause larger than oneself can inspire leadership and make a significant impact. Notable Quotes: "You have to understand that everything in life starts with the people. You can't do it alone; nobody can do it alone." "Preparation will prevent chaos. You want to prevent unnecessary stress in what you're doing, figure out what's the best way to be prepared." "Do as much as you can on the front end so that you have more flexibility as you get closer toward whatever your proverbial race is." "You have to create a consistent environment for your team. Consistency comes from preparedness." "If you can be a person, you don't have to have skills in life to believe in something. It doesn't matter what your cause is." To Donate to the National Ovarian Cancer Coalition >> CLICK HERE If you're looking to sharpen your mindset and achieve your goals, we've got you covered. Download our FREE Mindset Resources to get started on your journey to personal growth. Don't forget to check out our exclusive Shark Theory Apparel and Books for more tools and inspiration. Interested in taking your organization to the next level? Book Baylor to speak to your organization or at your next event. Mindset Matters - Let's make yours Unstoppable!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 16, 2025.Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women's Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., and Seagen and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CVY865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Conversation w/ Nancy Long, RN, CRNP, Annapolis Volunteer Market Coordinator, National Ovarian Cancer Coalition (NOCC), about ovarian cancer types and stages, risk factors, symptoms, screening, treatment, and prognosis; also, NOCC programs and services.

The Melanated Archives Podcast is back!!!!!! Kendra & Brandon return this week with part one of a two-part series highlighting the impact and importance of artistic mentors. In this episode, Kendra sits down to chat with award-winning actress, singer, activist, & Broadway giant Valisia LeKae, who wowed audiences and garnered a Tony & Grammy nomination for her portrayal of Diana Ross in the original Broadway company of MOTOWN THE MUSICAL. A cancer survivor, In 2014 she was named the spokesperson for the National Ovarian Cancer Coalition, an organization she worked closely with after being diagnosed with the disease in 2013. You do not want to miss this inspiring conversation about triumph, agency, and leading with a spirit of kindness and gratitude. Join us as we dig in the crates for episode 105 of The Melanated Archives Podcast. This Episode's Guests Include: Valisia LeKae: Instagram/Twitter - @valisialekae Website: ⁠https://www.valisialekae.com/⁠ Theme Music: Funky Suspense - courtesy of Bensound.com Follow Our Show & Our Hosts: TMA Instagram: @themelanatedarchives TMA Website: https://www.themelanatedarchives.com/ Kendra Holloway: Instagram - @kendra2shay Brandon Rachal: Instagram - @brandonrachal_ --- Support this podcast: https://podcasters.spotify.com/pod/show/themelanatedarchives/support

Been a while since we have been in the podcast facility at GRP Studios in Longwood, but Episode 98 of the Check Your Six podcast was fantastic. I had Nikki Coppola with the National Ovarial Cancer Coalition(NOCC) in the studio along with her very special guest, a breast cancer and ovarian cancer survivor Barbara Kramer.I learned a lot with these two women in the studio, first about the silence that comes with ovarian cancer and the other is the fighter mentality that both of these women possess. Nikki has a servants heart and a passion for helping others in creating hope and a better life for victims of all kinds of circumstances. Barbara was incredible just in the way that she described some of the things that she has gone through. Everyone knows about other cancers but it seems that ovarian cancer does not get the recognition and can be a tremendously challenging battle for women. Loved being able to talk with these two women and do what we can to bring attention to this terrible disease.

Key Takeaways:  1. Overview of ovarian cancer.  2. Karen's journey and experience of building the National Ovarian Cancer Coalition (NOCC) and the power of the community 3. The science and symptoms of ovarian cancer; building awareness and education resources for women About Karen Young and the National Ovarian Cancer Coalition Karen Young has been working in the nonprofit sector for more than 35 years and has been the Midwest Regional Manager for the National Ovarian Cancer Coalition for more than a decade. Located in Chicago, she oversees six states in the Midwest including Illinois, Indiana, Iowa, Missouri, Kentucky, and Tennessee. Ms. Young is passionate about the work she does with survivors. Ovarian cancer is one of the leading gynecologic cancers for women and is very often diagnosed in the latter stages. There is no early detection test for this cancer and the programs and services that the NOCC provides are crucial for that reason. She enjoys community collaboration to find the most meaningful partnerships to support her teal community. The Midwest region has quite an array of programs and services available to its survivors and serves over 700 women in the region. Ms. Young has a large corps of volunteers helping to execute programs and services in her area including free meals, free counseling, and financial assistance as well as educational programs and support groups. The chapter offers a variety of opportunities for survivors to meet each other and support one another especially through events like their annual Midwest Together in Teal walk to be held October 15th. Quotes At 2min and 10 seconds “Being one of her primary caregivers, and going through that experience, just really gravitated towards wanting to work with a cancer organization. And I knew nothing about ovarian cancer. But it was because of my mom that it interested me.” At 5min and 20 seconds “The pandemic pushed a lot of nonprofits, including us, you know, out of our comfort zone to reinvent ourselves to go virtual with everything and everything that we do. And the simple fact is, we were starting to identify some of the most basic needs.” At 14 mins and 07 seconds “In fact, the reason why the rate is so high for late stage diagnosis is because there is no reliable early detection test at all, hasn't been in years, they're still working on trying to find one. And even though there are tests that you can get if you suspect like let's say you have symptoms and you go and talk to your general doctor or even your gynecologist and you suspect that maybe you have ovarian cancer, there are some things that they can do to verify whether you do or not, but they are not reliable enough to become an early detection test that they would recommend for us annually every year.” At 23mins and 47 seconds “We talk about the trust and the relationship that we have with our medical professional, you know whether or not you can really feel comfortable that you're getting the best care and they are going to guide you and tell you what you need to know. And if it's really not important at this time, then don't bother me with those details. I can sleep better at night, if I don't know.” Resources An Animated Patient's Guide to Ovarian Cancer - https://nocc.ovarian.org/animated-patient-guide Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support

Happy Mother's Day to All Those Fantastic Moms out there!  It's also World Ovarian Cancer Day today, and in this valuable episode, you'll discover a few of the risk factors for Ovarian Cancer.  You also need to find out the symptoms for Ovarian Cancer because the Pap Test does Not find it!  Learn about some of the tests that are used to find Ovarian Cancer, and don't miss the crucial time to discuss your fertility concerns before cancer treatment.  Joy concludes this episode by sharing an inspiring story on Mother's Day from the National Ovarian Cancer Coalition web site.  Their site also offers Ovarian Cancer Support.      Support the show

Dr. Jeanine Cook-Garard learns about Ovarian Cancer, and The National Ovarian Cancer Coalition, whose mission is to save lives through the prevention - and cure - of ovarian cancer, and to improve the quality of life for survivors and their caregivers. Her guests are Stefanie Taylor, the Northeast Senior Regional Manager of the National Ovarian Cancer Coalition, and 'Vesna,' a woman from Long Island who is an Ovarian Cancer survivor.

On this Plugged Into Long Island, Tori spoke with Dr. Antoinette Sakaris of South Shore University Hopsital, Valerie Berger of Southside/Huntington Hospital, National Ovarian Cancer Coalition Chapter Manager Stefanie Taylor, and ovarian cancer survivor Vesna. The all-ladies panel talked about how to spot the signs for ovarian cancer, and the ways in which women can reduce their risk of getting it.

Jay Don Reeve and his wife Rhonda are holding a Jack & Jill benefit crappie tournament on Lake O' The Pines in Texas on October 23, 2021. This is to benefit the National Ovarian Cancer Coalition. Visit JackNJillClassic.com for more info You can also message Rhonda Reeve on Facebook.

My Friend Sarah is an amazing human being.  Last year in a span of less than 60 days she went from being able to run 3 miles to running a 50k, 31 miles!  This year, she's not running for herself, she's running the New York City Marathon to support the National Ovarian Cancer Coalition.  Our discussion on running sheds light into how we as humans, can change the world. In this episode, we'll discuss: Becoming fueled by helping others The best way to tackle adversity Controlling what you can control How to gain support in life Changing the World through your gift If you support great people doing great things, consider making a tax-deductible donation to the NOCC HERE. If you want to follow along with Sarah's running journey and see the lives she's impacting, you can FOLLOW HERE #NOCCteamTeal

Are you aware of your family's cancer history? Did you know genetic testing for cancer markers can save your life? I'm diving into these questions with Patient Insights & Advocacy Advisor at the National Ovarian Cancer Coalition, Ilana Feuchter. As a stage 2C ovarian cancer survivor, Ilana is dedicated—both personally and professionally—to raising awareness of genetic testing and self-advocacy. In this episode, she's sharing her journey with BRCA1, what steps she took to be proactive about her cancer risks (and what they revealed), and the importance of knowing your family cancer history in order to be the BEST advocate for yourself.  We're exploring:   Why BRCA1 and BRCA2 are problematic for women AND men Ilana's choice to undergo a prophylactic salpingo-oophorectomy (and later a prophylactic mastectomy) How a surprise ovarian cancer diagnosis changed the trajectory of her life Why you can never say you are cancer free with ovarian cancer  What still needs to be addressed in the survivorship journey A SURPRISING statistic about genetics and ovarian cancer (and what this means for anyone with a family history) Ilana's TOP TIP to find your people and make your cancer journey easier One of the silver linings to her cancer journey And so much more! Join me for a Coffee Chat here: https://fitnessdesignsolutions.as.me/CoffeeChat Follow me on Instagram to get the latest updates on the podcast: https://www.instagram.com/thejennifercochran/   Continue the conversation in my free private Facebook group, Surviving is JUST the Beginning: https://www.facebook.com/groups/SurvivingisJUSTtheBeginning/

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView's unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView's unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView's unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView's unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView's unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView's unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.

06- Janice Skidmore is the owner of Write Mind Creative; a company created to provide affordable, customized, quality branding, brand development, and social media management for entrepreneurs, and small businesses. She is a Marine Corps Veteran, German Shepard fanatic, dancing freak, manager of the newly forming New Mexico Chapter of “Teal Hearts Peer-To-Peer Network” via the National Ovarian Cancer Coalition, and is herself, an Ovarian Cancer Survivor. You can reach Janice at: IG & FB @writemindcreative Email Janice@writemindcreative Regarding ovarian cancer FB @nmtealheartsnetwork --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/ben-wolff/message Support this podcast: https://anchor.fm/ben-wolff/support

MJ's got a full house with the National Ovarian Cancer Coalition! They go in-depth about the symptoms of ovarian cancer, things women should be aware of (like how a Pap test does not detect ovarian cancer), and much more. Their event Together In Teal No Boundaries is on September 26 at 7 PM and will highlight the most inspiring and remarkable stories being told every day in our communities.

MJ talks with the National Ovarian Cancer Coalition Long Island Chapter about their Together In Teal Run-Walk on Saturday, September 21st at Belmont Lake State Park.

Olivia Fonti sits down with Stefanie Taylor and Serena Kindler from the National Ovarian Cancer Coalition and Dr Benjamin Schwartz. Valerie Burger from Northwell Health. They discuss the organizations upcoming events as well as what The National Ovarian Cancer Coalition is all about and how it helps those stricken with ovarian cancer.

Long known and well respected as an actor on popular shows like CSI: Miami and All My Children, Eva LaRue has earned Emmy and NAACP nominations for her portrayals of strong women. Eva has kept busy with other notable works over the years in TV and movies, and recently added writing and producing to her resume. Currently, Eva is the spokesperson for Tahirih Justice Center, helping women and girls fleeing gender based violence. Most recently she and her teen daughter Kaya have been working with South American refugee children at the San Fernando Valley Children's Refugee Center, where they provide counseling to young teens who have traversed thousands of miles alone and endured horrific conditions along their journey. Eva previously served as the National Spokesperson for Beckstrand Cancer Foundation and as the Spokesperson for the National Ovarian Cancer Coalition. An avid animal lover, she has participated in a number of charities offering rescue and assistance to neglected dogs and cats.       In her spare time, Eva is an avid travel enthusiast and a passionate activist. Visit https://evalarue.luxury. Get the Inclusion Revolution CD by Sister Jenna.  Like America Meditating. Download our free Pause for Peace App for Apple or Android

Donna Donna sits down with Stefanie Taylor of the National Ovarian Cancer Coalition, as well as ovarian cancer survivor Caitlin Nespoli, RN Valerie Berger and Doctor Schwartz. The group discusses ovarian cancer as a whole, including how to get tested, and what symptoms women should watch out for. They also discuss the NOCC's Run/Walk event to break the silence on ovarian cancer that will take place on 9/23 at Belmont Lake State Park.

Samost JFCS and the National Ovarian Cancer Coalition in conjunction with The Cancer Connection presented a roundtable discussion, "WOMEN AND OVARIAN CANCER: What You Need to Know Now!" Download the podcast here (180 mb mono MP3 file, 02:11:07 duration). Featured Speakers and Time Codes 00:00:10 - 00:02:03 Program intro and information, Steve Lubetkin of Professsional Podcasts LLC. 00:02:03 - 00:03:37 Opening Remarks: Margery Dannenbaum, JFCS Staff, Cancer Connection Coordinator +1 (856) 424-1333 Susan Bass Levin 00:03:37 - 00:18:39 Moderator: Susan Bass Levin, Commissioner of New Jersey Department of Community Affairs and former Mayor of Cherry Hill Township, an ovarian cancer survivor. 00:18:39 - 00:59:06 Dr. Randolph Deger a noted gynecological oncologist from Virtua Gynecology Oncology Specialists. 00:59:06 - 01:01:29 Susan Bass Levin makes additional comments, introduces Bridget Legrazie, director of Fox Chase Virtua Family Risk Assessment Program 01:01:29 - 01:21:48 Bridget Legrazie Cancer Survivors 01:22:03 - 01:22:44 Susan Bass Levin introduces four cancer survivors to relate their personal experiences. 01:22:44 - 01:30:41 Linda Xerri, first diagnosed 14 months ago with Stage IV 01:30:41 - 01:44:11 Lynn Kaplan, first diagnosed six years ago at State IV-B 01:44:11 - 01:52:39 Karen Mason, first diagnosed six years ago, Stage III-C 01:52:46 - 01:57:07 Diane Steinberg, first diagnosed 12 years ago at stage I 01:57:07 - 02:09:56 Question and answer period, Susan Bass Levin moderates and closes the program 02:09:56 - 02:10:46 Steve Lubetkin concludes the podcast and provides contact information for Samost Jewish Family and Childrens Service. Keywords: jfcs,jewish,federation,ovarian,cancer,bass levin,cherry hill,nj,new jersey,woman,family,survivor,carcinoma A production of Professional Podcasts LLC, Cherry Hill, NJ